AstraZeneca: positive results in breast cancer

(CercleFinance.com) - On Monday AstraZeneca announced that Enhertu, the antibody-conjugate that it is developing with Japan's Daiichi Sankyo, has shown positive results in a trial of patients with advanced breast cancer.


The biopharmaceutical company says the phase III study met its primary endpoint by significantly improving (both clinically and statistically) the duration of progression-free survival in patients.

The trial's secondary endpoint, i.e. improvement in overall patient survival, was also met.

The trial, dubbed "Destiny-Breast02", compared the efficacy of Enhertu against a physician-preferred treatment of choice for HER2-positive, non-operable and/or metastatic breast cancer in patients already treated with Roche's Kadcyla.

AstraZeneca plans to present this data at an upcoming medical meeting.


Copyright (c) 2022 CercleFinance.com. All rights reserved.